preprints.org > life sciences > biochemistry > doi: 10.20944/preprints202206.0139.v1

Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Version 1 : Received: 7 June 2022 / Approved: 9 June 2022 / Online: 9 June 2022 (08:29:40 CEST)

Leukemia represents as one of the most common primary malignancies of the hematologic system in both children’s and adults and remains a largely incurable or relapse disease. The elucidation of disease subtypes based on mutational profiling, has not improved clinical outcomes. IDH1/2 are key enzymes of TCA cycle that produces α-ketoglutarate (αKG), however their mutated version, are well reported in various cancer types including leukemia, produces D-2 hydroxyglutarate (D-2HG), an oncometabolite. Recently, some studies have shown that wild type IDH1 is highly expressed in non-small cell lung carcinoma (NSCLC), primary glioblastomas (GBM) and several hematological malignancies and corelates with disease progression. In this work, we have showed treatment of wild type IDH1 leukemia cells with specific IDH1 inhibitor switched leukemic cells towards gly-colysis from oxidative phosphorylation (OXPHOS) phenotype. We also noticed reduction in αKG in treated cells possible suggesting inhibition of IDH1 enzymatic activity. Further, we found that IDH1 inhibition reduces the metabolites related to one carbon metabolism, essential to maintain global methylation in leukemic cells. Finally, we observed that metabolic alteration in IDH1 inhibitor treated leukemic cells promotes reactive oxygen species (ROS) formation along with loss of mito-chondrial membrane potential, leading towards apoptosis in leukemic cells. Overall, we showed that wild type IDH1 targeting in leukemic cells promote metabolic alterations that can be exploited for combination therapies for better outcome.

Leukemia; Metabolomics; IDH; OXPHOS

LIFE SCIENCES, Biochemistry